2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AiRWA Inc. (Nasdaq: YYAI) received a Nasdaq letter on August 24, 2026, saying it breached a listing rule by not filing its annual report on Form 10-K for the year ended April 30, 2026. The company blamed the delay on the time needed to consolidate a significant acquired business, and says the notice has no immediate effect on trading but that the filing and compliance are not assured.
Nasdaq letter dated August 24, 2026 cites Listing Rule 5250(c)(1) for the late 10-K.
Company must submit a compliance plan by October 23, 2026; Nasdaq may then grant an extension to January 25, 2027.
Company expects to file the 10-K before October 23, 2026, but the filing says there can be no assurance it will regain compliance.
Oragenics said NYSE American notified it on August 26, 2026 that it is below the continued listing standards for stockholders' equity. The company reported stockholders' equity of $3.7 million at June 30, 2026, and the exchange requires $6 million because the company had net losses in its five most recent fiscal years. The notice does not immediately affect the listing, but if the company does not meet the requirements, it could face delisting, which the filing says could reduce the stock's liquidity and market price.
Stockholders' equity was $3.7 million at June 30, 2026; the NYSE American standard cited requires $6 million.
A compliance plan is due to NYSE American by September 25, 2026, and the company must regain compliance by February 25, 2028.
Shares continue to trade as OGEN with a ".BC" (below compliance) designation during the plan period.
The company says it will endeavor to undertake a transaction in the future to achieve compliance, but gives no assurance it will succeed.
Socket Mobile received a Nasdaq notice dated August 24, 2026, saying it no longer meets the $2.5 million minimum stockholders' equity requirement, based on $2,382,624 reported in its June 30, 2026 quarterly report. The company must submit a compliance plan by October 8, 2026, and its stock continues to trade on the Nasdaq Capital Market under SCKT for now.
Stockholders' equity of $2,382,624 versus a $2.5 million Nasdaq minimum
Company also did not meet alternative standards: $35 million market value of listed securities or $500,000 net income from continuing operations
Compliance plan due October 8, 2026; Nasdaq may grant up to 180 calendar days if it accepts the plan
No immediate effect on listing or trading of SCKT common stock
GeoVax Labs received a Nasdaq Staff Determination Letter on August 27, 2026, stating Nasdaq will delist its common stock because the bid price stayed below $1.00 and the company is not eligible for the customary 180-day compliance period after its January 2026 reverse split. The company plans to request a hearing before the Nasdaq Hearings Panel, which would stay further action and keep the stock trading during the appeal, but the filing says there is no assurance the panel will grant continued listing.
Nasdaq determined the closing bid price was below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026.
The company effected a 1-for-25 reverse stock split on January 12, 2026, which made it ineligible for the 180-day compliance period.
Absent a timely hearing request, trading is expected to be suspended at the opening of business on September 8, 2026; the hearing request deadline is September 3, 2026.
My Size, Inc. received a Nasdaq letter on August 25, 2026, saying its stockholders' equity of $2,347,000 as of June 30, 2026 fell short of the $2,500,000 minimum for continued listing. The letter has no immediate effect on the listing, but the company must submit a compliance plan by October 9, 2026, and the Staff may grant an extension through February 21, 2027 if the plan is accepted.
Reported stockholders' equity as of June 30, 2026: $2,347,000 versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Compliance plan due October 9, 2026; the company plans to submit it on time
If accepted, extension possible through February 21, 2027; if not accepted or compliance is not regained, Staff would issue a delisting determination, which a hearing request would stay
Nasdaq staff determined to delist Jupiter Neurosciences' common stock from the Nasdaq Capital Market after the company did not regain compliance with the $35,000,000 minimum market value of listed securities by August 25, 2026. The company intends to appeal to the Nasdaq Hearings Panel and expects the hearing request to stay further action, but it cannot assure that the appeal will succeed. Separately, the company regained compliance with the $1.00 minimum bid price requirement, though the delisting threat remains.
Nasdaq notice received August 27, 2026 states the Staff determined to delist the common stock from The Nasdaq Capital Market.
Market value of listed securities was below the $35,000,000 minimum; the compliance deadline was August 25, 2026.
Company intends to request a hearing before the Nasdaq Hearings Panel and expects this to stay further action; success is not assured.
Closing bid price was at least $1.00 for 10 consecutive business days, August 13 through August 26, 2026, and the bid price matter is closed.
KALA BIO received a Nasdaq Staff Determination Letter on August 27, 2026, stating its common stock closed below $1.00 for 30 consecutive business days and it is out of compliance with the minimum bid price rule. Because the company effected a 1-for-50 reverse stock split on May 11, 2026, it is not eligible for a standard 180-day compliance period, and the company plans to request a Nasdaq Hearings Panel review, which would stay any delisting action while pending.
Nasdaq Staff determined the stock closed below $1.00 from July 16, 2026 through August 26, 2026, 30 consecutive business days.
No 180-day compliance period is available because the company effected a 1-for-50 reverse stock split on May 11, 2026.
KALA BIO intends to timely request a hearing before the Nasdaq Hearings Panel; a timely request stays suspension or delisting pending the Panel's decision.
The company states there is no assurance the Panel will grant continued listing or that it will regain compliance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.